Featured Company : Cannabis Science ( CBIS - OTC )

Cannabis Science ( CBIS - OTC ) recently hit $0.065 on high volume topping 41 million shares, and is presently consolidating . We expect this company to again attempt a breakout above its yearly high. This company has the goods , a highly experienced  management team and a rapidly expanding market place. Serious investors should ride the next wave and place these shares on their BUY LIST  

Cannabis Science Canada recently initiated operations , acquiring land and licenses from operators already doing business in Canada. We anticipate an aggressive expansion into Canada propelling the shares still higher.

Cannabis Science’s primary objective is to research and develop U.S. Food and Drug Administration (FDA)-approved, cannabinoid-based medicine
to fight a number of targeted critical ailments, including various Cancers, Neurological Conditions, PTSD, Sleep Deprivation, Chronic Pain, HIV/AIDS, Autism, Parkinson’s Disease, Epilepsy, Chronic Obstructive Pulmonary Disease (COPD), and others.

Cannabis Science and its collaborators are well underway on a number of research projects targeting Lung Cancer, Pancreatic Cancer, Chronic Pelvic Pain, and Oro-bucco-lingual Dyskinesias. MORE NEWS ON CBIS



Cannabis sector higher after Tilray reports earnings

  • Canadian cannabis producer Tilray reported fourth-quarter revenue of $15.5 million.
  • Results were buoyed 2018 sales to $43.1 million, up 110 percent from last year.
  • Tilray stock rallied following the top-line beat.

Shares of Tilray jumped after the company reported that its cannabis sales more than doubled over the last year.

Tilray on Monday reported fourth-quarter revenue of $15.5 million, buoyed 2018 sales to $43.1 million — up 110 percent from last year. The surge was driven by bulk sales, the first months of the legal adult-use market in Canada and accelerated wholesale exports, according to its latest financial update. Analysts had expected fourth-quarter sales of $14.1 million.

Our team made significant progress on our long-term initiatives including increasing production capacity, expanding and strengthening strategic partnerships and acquiring complementary businesses to accelerate our future growth and leadership position in medical and adult-use cannabis,Tilray CEO Brendan Kennedy said of the company’s financial report.

Net loss for the quarter was $31 million, or 33 cents per share, compared to $3 million, or 4 cents per share, for the prior-year period. The company also said that the number of kilograms of cannabis and derivative products increased nearly three-fold to 2,053 from 694 kilograms compared to the fourth quarter of 2017.

Kilograms sold in 2018 increase over two-fold to 6,478 from 3,024 in the prior year.

The most recent quarter was busy for Tilray, which expanded strategic partnerships with a number of global partners.

First, it expanded its alliance with Sandoz, a division of Swiss drugmaker Novartis, in an effort to increase access to medical cannabis to patients around the world. Tilray said it plans to work with Novartis’ generic drug business and supply non-smokable and non-combustible medical cannabis products where legal.

The Canadian company also disclosed a research and development partnership with Budweiser-parent AB InBev focused on non-alcohol THC and CBD beverages. Each company intends to invest up to $50 million, for a total of up to $100 million, Tilray said.

ETF 19.9% GAIN

The ETFMG Alternative Harvest ETF ( MJ ) was trading at $39.00 per share recently. Year-to-date, MJ has gained 19.91%, versus a 6.67% rise in the benchmark S&P 500 index during the same period.

MJ currently has an ETF Daily News SMART Grade of C (Neutral), and is ranked #59 of 75 ETFs in the Global Equities ETFs category.